

# WHO Drug Information

## Contents

<b>Personal Perspectives</b>			
Dr Hiroshi Nakajima, Acceptance Speech	55	For and against generic prescribing	67
Dr Halfdan Mahler, Rational Use of Drugs	56	Testing of an experimental vaccine against AIDS	68
		Cocaine: a dangerous drug	68
<b>Reports on Individual Drugs</b>			
Halofantrine in malaria	58		
<b>General Information</b>		<b>Regulatory Matters</b>	
Nebulizers for home use: bacterial contamination	61	<b>Drugs for human use</b>	
Amodiaquine resistance in <i>Plasmodium falciparum</i>	61	Alcohol-containing drugs: contraindicated for nursing mothers	69
Phenothiazines: extrapyramidal reactions	61	Alginate acid in over-the-counter preparations	69
Methotrexate: suspected interaction with trimethoprim	61	Allethrin-containing insecticides: warning for asthmatics	69
Insect repellants: toxicity after accidental ingestion	62	Canthaxanthin: withdrawal	69
Elastomers containing stannous octoate: potential toxicity	62	Cell therapy: prohibition	69
Acetylsalicylic acid in breast milk	62	Clebopride: warning on extrapyramidal symptoms	69
Anabolic steroids: evidence of increasing abuse	62	Contact lens cleaning fluid: warning on eye injury	70
Recommended composition of influenza virus vaccines for 1988-1989 season	63	Enoxacin/fenbufen: convulsions due to interaction	70
Testing for HIV antibody required for blood and blood products	63	Famotidine: revised product information	70
EEC: proposed extension of pharmaceutical directives	63	FD&C Red No.3 colorant: adverse reactions in animal study	70
Orphan drugs and "truly new" pharmaceuticals or biologicals licensed in 1987	64	FD&C Yellow No. 6 colorant: listing on beverage labels	70
Monitoring of ciclosporin blood levels	65	Fenfluramine: withdrawal	70
New clotting agent	65	Flunarizine: adverse effects	71
A new Salk-type vaccine manufactured using human cell cultures	65	Flupentixol decanoate: refusal of registration	71
Biotechnology patents: 20% increase in 1987	65	Ganciclovir: refusal of registration application	71
Traditional drugs in Japan	65	Glafenine and floctafenine: under prescription control	71
Reye's syndrome: decline in reported incidence	66	Ibuprofen: warning label	71
Post-exposure prophylaxis of rabies	66	Inactive ingredients: labelling requirements	71
Enalapril and atenolol equally effective in mild to moderate hypertension	66	Insulin: no longer indicated in insulin shock therapy	72
Heart attacks: reducing the risks and increasing the chance of survival	67	Isotretinoin: birth defects	72
		Lormetazepam: registration refusal	72
		Nonsteroidal anti-inflammatory agents: restrictions	72
		Oxeladin and promethazine available over-the-counter in France	73